Benzinga | Mar 9, 2021 09:15AM EST

Guggenheim Downgrades Five Prime Therapeutics to Neutral, Announces $38 Price Target

Guggenheim analyst Etzer Darout downgrades Five Prime Therapeutics (NASDAQ:FPRX) from Buy to Neutral and announces $38 price target.